Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib, Tislelizumab and RALOX-HAIC in Advanced HCC
NCT05954897Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, tislelizumab in hepatocellular carcinoma (HCC), sponsored by Guangdong Provincial People's Hospital. Started Sep 2023; status: recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05954897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954897.